A high-sensitivity test in the assessment of adrenocortical insufficiency: 10 microg vs 250 microg cosyntropin dose assessment of adrenocortical insufficiency.

González-González JG, De la Garza-Hernández NE, Mancillas-Adame LG, Montes-Villarreal J, Villarreal-Pérez JZ

The Journal of endocrinology1 Nov 1998Cited by 20 (Europe PMC)

PMID9795368DOI10.1677/joe.0.1590275PepBankPUB-09795368

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cosyntropin.

01HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In healthy subjects, peak cortisol did not differ significantly between low-dose and standard-dose cosyntropin tests.
In plain wordsIn healthy people, peak cortisol did not differ significantly between low-dose and standard-dose cosyntropin tests.
Peptide
Cosyntropin
Outcome
No significant changePeak serum cortisol
Study
n = 46
Comparator
250 microg cosyntropin
Outcome group
Diagnostic test performance · Endocrine and hormones
Source sentences
Summary
On comparing low- and standard-dose cosyntropin testing in healthy subjects there were no statistical differences in baseline and peaks of serum cortisol.
1 context sentence(design, population, supporting numbers)
Summary · context
The subjects were 83 healthy people and 37 patients, the latter having Addison's disease (11), pituitary adenomas (7), Sheehan's syndrome (9) and recent use of glucocorticoid therapy (10). Forty-six healthy subjects and all patients underwent low- and standard-dose cosyntropin testing. In addition,…
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0979536801
02HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In Addison's disease, low-dose cosyntropin identified abnormal cortisol in 2 of 11 cases with normal standard-test values.
In plain wordsIn Addison's disease, low-dose cosyntropin identified abnormal cortisol in cases with normal standard-test results.
Peptide
Cosyntropin
Outcome
Not applicableAbnormal cortisol classification in Addison's disease
Study
n = 11
Comparator
250 microg cosyntropin
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Discordant cases
2 cases
11 Addison's disease cases
Source sentences
Summary
In the group of patients, 2 out of 11 cases of Addison's disease showed normal cortisol criterion values during the standard test but abnormal during the low-dose test.
1 context sentence(design, population, supporting numbers)
Summary · context
The subjects were 83 healthy people and 37 patients, the latter having Addison's disease (11), pituitary adenomas (7), Sheehan's syndrome (9) and recent use of glucocorticoid therapy (10). Forty-six healthy subjects and all patients underwent low- and standard-dose cosyntropin testing. In addition,…
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0979536802
03HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In patients and controls, low-dose cosyntropin had better sensitivity than standard-dose testing at 30 min.
In plain wordsIn patients and controls, low-dose cosyntropin was more sensitive than standard-dose testing at 30 min.
Peptide
Cosyntropin
Outcome
IncreaseSensitivity at 30 min
Study
n: not reported in source
Comparator
250 microg cosyntropin
Outcome group
Diagnostic test performance · Endocrine and hormones
Source sentences
Summary
In our group of patients and controls, the statistical analysis displayed a better sensitivity of the low-dose vs standard-dose ACTH test at 30 and 60 min.
1 context sentence(design, population, supporting numbers)
Summary · context
The subjects were 83 healthy people and 37 patients, the latter having Addison's disease (11), pituitary adenomas (7), Sheehan's syndrome (9) and recent use of glucocorticoid therapy (10). Forty-six healthy subjects and all patients underwent low- and standard-dose cosyntropin testing. In addition,…
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0979536803
04HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In patients and controls, low-dose cosyntropin had better sensitivity than standard-dose testing at 60 min.
In plain wordsIn patients and controls, low-dose cosyntropin was more sensitive than standard-dose testing at 60 min.
Peptide
Cosyntropin
Outcome
IncreaseSensitivity at 60 min
Study
n: not reported in source
Comparator
250 microg cosyntropin
Outcome group
Diagnostic test performance · Endocrine and hormones
Source sentences
Summary
In our group of patients and controls, the statistical analysis displayed a better sensitivity of the low-dose vs standard-dose ACTH test at 30 and 60 min.
1 context sentence(design, population, supporting numbers)
Summary · context
The subjects were 83 healthy people and 37 patients, the latter having Addison's disease (11), pituitary adenomas (7), Sheehan's syndrome (9) and recent use of glucocorticoid therapy (10). Forty-six healthy subjects and all patients underwent low- and standard-dose cosyntropin testing. In addition,…
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0979536804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.